L ower urinary tract symptoms (LUTS) are common and can affect up to 30% of men over the age of 65 years. The term LUTS encompasses storage, voiding and post-micturition symptoms; all of which can produce a significant impact on quality of life. There are many causes of LUTS. In addition to pathology within the urinary tract, LUTS can also be caused by medication, diabetes, heart failure, obstructive sleep apnoea and high levels of fluid intake. A common urological cause for symptoms is benign prostatic hyperplasia (BPH); a benign enlargement of the prostate gland that affects 30% of men between 50 and 60 years in age and up to 90% of men over the age of 85 years. This article aims to assist GPs to identify and understand the patient presenting with prostatic symptoms, and effectively manage BPH in a primary care setting.
The GP curriculum and benign prostatic hyperplasia Clinical example 3.07: Men's health requires GPs to: . Know that men currently tend to be poorer users of all primary care provision and that service providers have a statutory duty to achieve gender-equitable use of services where appropriate . Manage primary contact with patients who have a male genito-urinary problem . Identify how the extended role of the practice nurse, health visitor and other surgery staff is effective in delivering health promotion for men Anatomy and function of the prostate gland The prostate is an exocrine gland of the male reproductive system and in a healthy adult male approximates to the size of a walnut. It is situated posterior to the pubic symphysis, below the urinary bladder and its posterior wall can be felt during a digital rectal examination. Two thirds of the prostate is glandular tissue and the remaining third consists of fibro-muscular tissue. The glandular tissue of the prostate secretes a milky white alkaline fluid that contributes to around 50-60% of seminal fluid. The secretion is alkaline which neutralises the acidity of vaginal sections and promotes sperm survival. Also included in the secretion are carbohydrates needed for aerobic respiration of spermatozoa, proteolytic enzymes and prostate-specific antigen.
The ejaculatory ducts enter into the upper posterior part of the gland to open into the urethra. During ejaculation, sperm are secreted from the duct deferens into the male urethra via the ejaculatory ducts. At orgasm, the smooth muscle in the prostate contracts to push semen along the urethra. Men can achieve orgasm through stimulation of the prostate gland. Anatomically the prostate can be split into 'zones' or 'lobes' as shown in Fig. 1 The exact pathogenesis of BPH is unclear. However, it does appear to be in part mediated by hormonal influences. Enlargement of the prostate is dependent on dihydrotestosterone (DHT), a potent androgen. DHT is important in the development of the prostate gland and in maintaining a balance between cell proliferation and apoptosis.
The precursor of DHT is testosterone, which is produced in the Leydig cells of the testes. Testosterone is converted into DHT via the enzyme 5a-reductase, of which there are two isoenzymes: type 1 and type 2. Both present in the prostate. DHT binds locally to alpha 1-adrenergic receptors situated on the smooth muscle and capsule of the prostate, releasing growth factors and stimulating growth of prostatic tissue (see Fig. 2 ).
In BPH both the glandular and stromal tissues undergo hyperplasia. This most commonly occurs in the transitional zone, adjacent to the prostatic urethra. The expanding prostate compresses the urethra and can give rise to voiding problems. Due to the obstruction of urinary flow, the bladder wall may become irritable and hypertrophied. Overactive bladder syndrome (OABS) can then develop, leading to symptoms of urgency. Ineffective detrusor contractions can also lead to incomplete voiding and residual volumes. Lower urinary tract symptoms (LUTS) can be categorised into storage, voiding and post-micturition symptoms (see Table 2 ). National Institute for Health and Care Excellence (NICE) guidelines on LUTS recommend asking the patient to conduct a urinary volume frequency chart as part of the initial assessment (NICE, 2010) . Using a standardised symptom score sheet such as the International Prostate Symptoms Score (IPSS) may also be useful to measure change or improvement of LUTS in future consultations. A score of 0-7 indicates mild symptoms, 8-19 moderate symptoms and greater than 19, severe symptoms. ......................................................................................................................................................................................................... During the initial assessment, it is important to take a thorough past medical history to identify other urological and non-urological causes of LUTS. Diabetes can present with increased frequency and polyuria. Neurological conditions, such as multiple sclerosis and spinal cord lesions, may present with urinary incontinence or retention. Mild heart failure can cause nocturia due to an increase in atrial natriuretic factor. Patients with sleep disturbance in obstructive sleep apnoea often report symptoms of noctura. Medical conditions that cause hypercalcaemia can also present with polyuria. Diabetes insipidus and functional polyuria can also lead to the excretion of large volumes of urine.
InnovAiT
It is important to review the patient's medication to identify any drugs that may be contributing to LUTS, for example diuretics or antimusarnics.
In addition to BPH, other urological conditions can cause LUTS. These include sexually transmitted infections, cystitis, renal and bladder stones, and urinary tract malignancies. Ask the patient about the presence of blood in the urine. Haematuria can be present with any inflammatory conditions of the urinary tract and prostate, including infections, stones, nephritis and tumours. NICE guidance for urgent referral for suspected urological malignancies (NICE, 2005) includes referral to a specialist with expertise in the management of urological malignancies anyone with painless macroscopic haematuria, those over the age of 40 with recurrent or persistent urinary tract infections, and those who are aged 50 years or over with persistent microscopic haematuria. Referrals for suspected cancer will be considered later on in this article. Examination will be largely guided by the patient's history. A general assessment of the patient would include measuring temperature and vital signs. An abdominal examination may also be indicated if suspecting renal or obstructive pathology. Examine for renal angle tenderness or masses and palpate the bladder to assess for urinary retention Some patients may require more intimate examinations such as a digital rectal (DRE) or genital examination. Patients should be counselled as to what the examination will entail and be offered a GP of the same gender if they prefer. A chaperone should be offered. A digital rectal examination is indicated for anyone with red flag symptoms. When performing digital rectal examination, assess the prostatic lobes for symmetry, size and smoothness. A normal prostate size in a young adult male is 20 g, which approximates to a finger's breadth. Ask the patient if the examination is painful, which may be indicative of prostatitis. Assess anal tone and perianal sensation at this time. Examining the external genitalia may be indicated if infective causes of LUTS are suspected. Take a urine dip to check for blood, nitrites, leucocytes and glucose, and send for microscopy and culture if there are concerns about infection. If you are concerned about renal impairment, offer men a blood test to check for urea, creatinine and electrolytes. For example, this may be appropriate in patients with a palpable bladder, nocturnal enuresis, recurrent urinary tract infections or renal stones.
Prostate-specific antigen testing in BPH
Prostate-specific antigen (PSA) testing in the context of a clinically benign enlarged prostate can be a difficult issue, with debates among the medical profession ongoing. It is therefore important to consider how a PSA level would meaningfully affect your management and have an open and honest discussion with the patient regarding the possible consequences of a raised PSA. In the context of assessing men with LUTS, NICE states that the measurement of PSA levels is only indicated if the patient specifically requests testing, has a malignant feeling prostate on DRE or has symptoms clinically suggestive of bladder outlet obstruction (NICE, 2013) . The European Association of Urology' (EAU) guidance (Gravas et al., Techniques such as urethral milking or bulbar massage can be taught to patients to help prevent post-micturition dribbling. In this method the patient is instructed to place two fingers behind his scrotum after micturition and massage in a forward and upward direction towards the penis. This allows the bulbar urethra to empty. Squeezing the pelvic floor muscles after micturition has also improves the leakage of urine. Double voiding (waiting a couple of minutes post micturition and then attempting to urinate again) may help patients to empty their bladder. For patients who have developed symptoms of OABS as a consequence of BPH, supervised bladder retraining can also be useful. Medication should be offered to men with moderate-tosevere LUTS and in patients where conservative management has been unsuccessful, and can be initiated in primary care. Pharmacological treatment may consist of alpha-blockers, 5a-reductase inhibitors, antimuscarinics for predominant OABS symptoms, desmopressin and furosemide for nocturnal polyuria and phosphodiesterase PDE Type-5 inhibitors. Several of these agents can be used in combination therapies, as outlined below.
Alpha-blockers
In moderate-to-severe voiding LUTS, alpha-blockers are the first line of treatment. Originally used to treat hypertension, they work by relaxing the smooth muscles of the prostate and the bladder neck, thereby reducing obstruction and improving the flow of urine. Effects should be noticed by 48 hours. The most commonly prescribed alpha-blockers include doxazosin, alfuzocin, tamsulosin and terazosin. Tamsulosin is the most selective for the alpha-1 a receptor, which is highly prevalent in the prostate.
Side effects of alpha-blockers include orthostatic hypotension (particularly with the less uroselective medications such as doxazosin and terazosin), headaches, nasal congestion, fatigue, dizziness and ejaculatory dysfunction.
5a-reductase inhibitors
In patients with bothersome LUTS and a prostate that is enlarged (30 g or PSA greater than 1.4 ng/ml), consider treatment with a 5a-reductase inhibitors such as finasteride or dutasteride. Their method of action is by blocking the conversion of testosterone to DHT, thus decreasing prostate growth and improving urinary flow.
The CombAT study (Roehbon, Siami, Barkin, Damiao, & Major-Walker, 2010) compared the efficacy of monotherapy with an alpha-blocker or a 5a-reductase inhibitor to combination therapy. The endpoint was a reduction in IPSS scores. It demonstrated that greatest improvement in symptom scoring was 27 months in the 5a-reductase inhibitor dutasteride versus 18 months with the alphablocker tamsulosin. It showed that combination therapy lead to a greater improvement in IPSS scoring than monotherapy alone. Therefore, in patients who are troubled with moderate-to-severe LUTS with an enlarged prostate, consider using initiating combination therapy in primary care. Table 3 shows the NICE guidance (NICE, 2010) on when to review the different medications available for treating LUTS.
Side effects of 5a-reductase inhibitors include decreased libido, ejaculator dysfunction and impotence. Currently, there is considerable debate about whether 5a-reductase inhibitors can protect against prostate cancer. Some studies have suggested that treatment lowers the risk, whereas others have linked it to an increased risk of diagnosing advanced prostate cancer. It is important to note that finasteride and dutasteride can reduce PSA levels by approximately 50%, which needs to be taken into account when assessing the risk of prostate malignancy.
Antimuscarinics
Antimuscarinics can be used if storage symptoms that persist despite treatment with an alpha-blocker. They act by decreasing the effects of acetylcholine on the bladder, reducing detrusor contraction and helping treat OABS. Commonly used antimuscarinics include tolterodine, solifenacin and oxybutynin. Caution needs to be taken in patients at risk of acute urinary retention; for example, elderly men with raised post-void residual volumes or a previous episode of retention. An antimuscarinic may be used as monotherapy for OABS symptoms, or in combination with an alpha-blocker following the failure of alpha-blocker monotherapy (Kaplan et al., 2005) .
The recently introduced alpha-blocker and antimuscarinic combination medication Vesomni TM is a modified release ..................................................................................................................................................................................................................... ..... tablet containing 6 mg of solifenacin and 0.4 mg of tamsulosin, and is licensed for use in the UK. A recent metaanalysis compared the use of dual anti-muscarinic and alpha-blocker therapy to alpha-blocker monotherapy in the treatment of BPH-related LUTS. They found greater reductions in IPSS scores and voiding frequency with dual therapy. There was, however, a reduction in urinary flow rate and increased post-void residuals (Filson, Hollingsworth, Clemens, & Wei, 2013) .
Tadalafil
The phosphodiesterase inhibitor tadalafil (Cialis) is licensed in the UK for the treatment of BPH and is particularly useful in patients who also have erectile dysfunction. It is taken as a once-daily 5 mg tablet. The method by which tadalafil improves BPH symptoms remains unclear. It should not be used in combination with an alpha-blocker due to the risk of lowering blood pressure, and should not be used in combination with nitrates.
Desmopressin
Desmopressin is a synthetic analogue of an anti-diuretic hormone (ADH). ADH acts on the distal convoluted tubule of the kidney, increasing its permeability to water and thus increasing water reabsorption and concentrating the urine. Demsopressin is listed in NICE guidelines (NICE, 2013) as a potential treatment for men with nocturnal polyuria, where other causes have been excluded and other medications have failed. It is currently an off-label treatment. Desmopressin is contraindicated in men with a history of cardiac insufficiency or those on other diuretic treatments. Caution should be taken in renal and cardiovascular disease. Desmopressin may cause hyponatraemia in the presence of inappropriate fluid intake. Medication can come in oral tablet and intranasal form.
Furosemide
The EAU advocates the use of a low-dose loop diuretic such as furosemide for the treatment of nocturnal polyuria. This should be administered in the mid-afternoon for optimal effect (Gravas et al., 2014).
Herbal therapies
The use of herbal therapies in treating the symptoms of BPH has long been a subject of investigation, with varied published reports of their usefulness in improving symptom scale scores or symptoms of BPH when compared to placebo. Various phytotherapeutic substances (i.e. pygeum africanum, cernilton, saw palmetto) have been subjected to a systematic review (Ishani, MacDonald, & Nelson, 2000) that concluded that the use of some these agents can improve the symptoms of BPH; however, studies that directly compare them to established pharmacological treatments (i.e. tamsulosin) are lacking. In a 2012 Cochrane review, in men with BPH, serenoa repens was shown to produce no greater effect than placebo in improving LUTS, American Urological Association symptom score index or prostate size (Wilt, Ishani, MacDonald, Rutks, & Stark, 2002) . Overall the NICE guidelines have not supported the use of herbal remedies as they are unlicensed and have conflicting evidence around efficacy (NICE 2010). If moderate or severe symptoms of LUTS still persist despite maximal-tolerated medical therapy, referral to secondary care for consideration of surgery may be appropriate. Surgical intervention should also be considered early in the presence of complications from BPH. These include recurrent urinary retention, obstructive uropathy and its seqeulae such as recurrent urinary tract infections, bladder stone and diverticulae. Surgical treatments may be categorised into invasive and more novel non-invasive transurethral options. Open surgery for BPH is now rarely performed, and is only considered for men with prostates greater than 80 g in weight.
Invasive and laser treatments NICE (2010) recommend monopolar or bipolar transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral vaporisation of the prostate (TUVP) or holium laser ennucleation of the prostate (HoLep) as possible surgical treatments for BPH, depending on the patients and urologists' preference and clinical suitability.
TURP remains the gold standard treatment for men with a 30-80 g prostate and is performed via diathermy. Inpatient stay is typically 2-5 days. Early complications of TURP include bleeding, infection, urinary retention post removal of the catheter, and incontinence. Late complications include urethral stricture, urinary retention or incontinence, retrograde ejaculation, and erectile dysfunction. Up to 10% of patients may need a repeat procedure within 5 years. TUIP is reserved for men with smaller prostates (30 g or less). TUVP uses a monopolar electric current to vaporise prostatic tissue. Studies have reported both methods to be comparable in effectiveness to TURP with lower complication rates.
Non-invasive treatments
In recent years laser treatments have evolved to treat BPH. Transurethrally, a laser is used to vaporise the prostatic adenoma, causing coagulative necrosis. NICE (2010) 
Prostatic stents and Urolift
The use of prostatic stents remains an alternative treatment for BPH in well-selected patients. They are primarily used in patients' unfit for surgery. Risk for stent migration precludes this from widespread use and they are rarely used. Recent evidence has shown benefit with the use of a prostatic urethral lift or 'Urolift' for the treatment of BPH-associated LUTS. This treatment has been incorporated into draft NICE guidance, which is due to be issued in September 2015. During the transurethral procedure, both prostatic lobes are secured in the retracted position to widen the urethral lumen. Lower rates of complications such as sexual dysfunction and incontinence have been reported.
Key points
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